Universitätsklinikum Essen

Identifying predictors of treatment response in major depressive disorder: A machine learning approach (2023) Amir F, Schrauder M Journal article Recommendations on the structure, personal, and organization of intensive care units (2023) Waydhas C, Riessen R, Markewitz A, Hoffmann F, Frey L, Böttiger BW, Brenner S, et al. Journal article Author Correction: Guidelines for Neuroprognostication in Adults with Guillain–Barré Syndrome (Neurocritical Care, (2023), 38, 3, (564-583), 10.1007/s12028-023-01707-3) (2023) Busl KM, Fried H, Muehlschlegel S, Wartenberg KE, Rajajee V, Alexander SA, Creutzfeldt CJ, et al. Journal article, Erratum SOP – Subkutane Medikamentengabe und Infusionen in der erwachsenen Palliativmedizin Version II (2023) Hense J, Przyborek M, Rosenbruch J, Ostgathe C, Wolf C Journal article Pediatric multi-drug-resistant tuberculosis in Germany – diagnostic and therapeutic challenges of an “orphan disease” (2023) Schäfer HL, Barker M, Follmann P, Günther A, Hörning A, Kaiser-Labusch P, Kerzel S, et al. Journal article Stromal-epithelial interaction induces GALNT14 in prostate carcinoma cells (2023) Czyrnik ED, Wiesehöfer M, Dankert JT, Wach S, Wagner M, Spahn M, Kruithof de Julio M, Wennemuth G Journal article Cardiovascular toxicity of the treatment of oncological diseases in children and adolescents: Position paper on aspects of cardiological care and aftercare Kardiovaskuläre Toxizität der Therapie onkologischer Erkrankungen bei Kindern und Jugendlichen: Positionspapier zu Aspekten der kardiologischen Betreuung und Nachsorge (2023) Neudorf U, Schönecker A, Apitz C, Koch D, Voges I, Rassaf T, Langer T, et al. Journal article, Review article Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification (2023) Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, et al. Journal article Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial (2023) Weller J, Schäfer N, Schaub C, Tzaridis T, Zeyen T, Schneider M, Potthoff AL, et al. Journal article Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. (2023) Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, et al. Journal article